Jens Chemnitz

957 total citations
20 papers, 527 citations indexed

About

Jens Chemnitz is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Jens Chemnitz has authored 20 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Hematology and 7 papers in Immunology. Recurrent topics in Jens Chemnitz's work include Hematopoietic Stem Cell Transplantation (7 papers), Lymphoma Diagnosis and Treatment (4 papers) and Acute Myeloid Leukemia Research (3 papers). Jens Chemnitz is often cited by papers focused on Hematopoietic Stem Cell Transplantation (7 papers), Lymphoma Diagnosis and Treatment (4 papers) and Acute Myeloid Leukemia Research (3 papers). Jens Chemnitz collaborates with scholars based in Germany, France and Austria. Jens Chemnitz's co-authors include Christof Scheid, Sebastian Theurich, Udo Holtick, Michael von Bergwelt‐Baildon, Nicole Skoetz, Alexander Shimabukuro‐Vornhagen, Claudia Wickenhauser, Michael S. von Bergwelt‐Baildon, Franz‐Georg Hanisch and Udo Roth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cochrane Database of Systematic Reviews.

In The Last Decade

Jens Chemnitz

20 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jens Chemnitz Germany	9	222	219	162	60	59	20	527
Sandra M. J. Paulissen Netherlands	9	72 0.3×	318 1.5×	96 0.6×	45 0.8×	19 0.3×	13	576
Nicole Engel Germany	12	153 0.7×	44 0.2×	92 0.6×	30 0.5×	53 0.9×	21	366
Mohammed S. Chaudhry United Kingdom	10	193 0.9×	369 1.7×	256 1.6×	35 0.6×	16 0.3×	17	614
Joanna Więckiewicz Poland	10	37 0.2×	413 1.9×	100 0.6×	17 0.3×	25 0.4×	13	663
Georgios Paterakis Greece	10	92 0.4×	101 0.5×	92 0.6×	96 1.6×	47 0.8×	32	368
Maria Giuseppina Cefalo Italy	14	133 0.6×	80 0.4×	85 0.5×	66 1.1×	58 1.0×	43	407
P. A. Veys United Kingdom	11	84 0.4×	172 0.8×	38 0.2×	23 0.4×	25 0.4×	16	350
Anna Lollies Germany	6	19 0.1×	214 1.0×	91 0.6×	52 0.9×	16 0.3×	8	418
Yosuke Masamoto Japan	10	125 0.6×	144 0.7×	67 0.4×	64 1.1×	14 0.2×	57	444
Hilde E. Groot Netherlands	12	55 0.2×	88 0.4×	39 0.2×	30 0.5×	21 0.4×	31	544

Countries citing papers authored by Jens Chemnitz

Since Specialization

Citations

This map shows the geographic impact of Jens Chemnitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Chemnitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Chemnitz more than expected).

Fields of papers citing papers by Jens Chemnitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Chemnitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Chemnitz. The network helps show where Jens Chemnitz may publish in the future.

Co-authorship network of co-authors of Jens Chemnitz

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Chemnitz. A scholar is included among the top collaborators of Jens Chemnitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Chemnitz. Jens Chemnitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ram, Ron, Christof Scheid, Odelia Amit, et al.. (2019). Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 104(9). 1798–1803. 6 indexed citations

Hartmann, J. T., Hans‐Georg Kopp, Viktor Gruenwald, et al.. (2019). Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. European Journal of Cancer. 124. 152–160. 23 indexed citations

Hartmann, J. T., Hans‐Georg Kopp, Viktor Gruenwald, et al.. (2018). Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma.. Journal of Clinical Oncology. 36(15_suppl). 11507–11507. 1 indexed citations

Herling, Marco, et al.. (2016). BKV Disease during the First 100 Days after Allogeneic Hematopoietic Stem Cell Transplantation - Results of a Screening Program and Retrospective Analysis. Blood. 128(22). 3403–3403. 3 indexed citations

Chakupurakal, Geothy, Petra Langerbeins, Joanna Schiller, et al.. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality—a single institution experience. Annals of Hematology. 94(10). 1717–1725. 2 indexed citations

Holtick, Udo, Alexander Shimabukuro‐Vornhagen, Geothy Chakupurakal, et al.. (2015). FLAMSA reduced‐intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. European Journal Of Haematology. 96(5). 475–482. 14 indexed citations

Holtick, Udo, Lukas P. Frenzel, Alexander Shimabukuro‐Vornhagen, et al.. (2014). CD4+ T cell counts reflect the immunosuppressive state of CD4 helper cells in patients after allogeneic stem cell transplantation. Annals of Hematology. 94(1). 129–137. 3 indexed citations

Holtick, Udo, Melanie Albrecht, Jens Chemnitz, et al.. (2014). Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database of Systematic Reviews. 2014(4). CD010189–CD010189. 100 indexed citations

Chemnitz, Jens, Geothy Chakupurakal, Udo Holtick, et al.. (2014). Pretransplant Comorbidities Maintain Their Impact on Allogeneic Stem Cell Transplantation Outcome 5 Years Posttransplant: A Retrospective Study in a Single German Institution. PubMed. 2014. 1–7. 5 indexed citations

10.

Theurich, Sebastian, Geothy Chakupurakal, Alexander Shimabukuro‐Vornhagen, et al.. (2013). Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis—A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 88(1). 178–186. 28 indexed citations

11.

Holtick, Udo, Lukas P. Frenzel, Sebastian Theurich, et al.. (2013). Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 122(21). 4588–4588. 2 indexed citations

12.

Wardelmann, Eva, Jens Chemnitz, & Clemens‐Martin Wendtner. (2012). Targeted Therapy of Soft Tissue Sarcomas. Onkologie. 35(s1). 21–27. 7 indexed citations

13.

Theurich, Sebastian, Kerstin Wennhold, Alexander Shimabukuro‐Vornhagen, et al.. (2012). CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation. Blood. 120(21). 4213–4213. 1 indexed citations

14.

Theurich, Sebastian, Kerstin Wennhold, Alexander Shimabukuro‐Vornhagen, et al.. (2012). Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. Journal of Clinical Oncology. 31(5). e59–e63. 45 indexed citations

15.

Theurich, Sebastian, Alexander Shimabukuro‐Vornhagen, Jens Chemnitz, et al.. (2012). Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database of Systematic Reviews. CD009159–CD009159. 44 indexed citations

16.

Schlaak, Max, Peter Kurschat, Alexander Shimabukuro‐Vornhagen, et al.. (2011). Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transplant Immunology. 25(2-3). 163–166. 9 indexed citations

17.

Bergwelt‐Baildon, Michael S. von, Alexey Popov, Tomo Šarić, et al.. (2006). CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 108(1). 228–237. 187 indexed citations

18.

Cornely, Oliver A., Jens Chemnitz, Karin Lemmer, et al.. (2001). Disseminated Neocosmospora vasinfecta Infection in a Patient with Acute Nonlymphocytic Leukemia. Emerging infectious diseases. 7(1). 149–152. 8 indexed citations

19.

Chemnitz, Jens, Aida Salameh, Christof Scheid, et al.. (2000). Thrombotisch-thrombozytopenische Purpura (Moschcowitz-Syndrom), verursacht durch Ticlopidin. Medizinische Klinik. 95(2). 96–100. 3 indexed citations

20.

Reiser, Marcel, Andreas Josting, Andreas Draube, et al.. (1999). Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplantation. 23(12). 1223–1228. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact